No Data
No Data
No Data
Sichuan Biokin Pharmaceutical Gets Clinical Trial Approval for Tumor Antibody Injection
Sichuan Biokin Pharmaceutical Enrolls First Patient in Phase 3 Trial of Anti-Cancer Treatment; Shares Slide 3%
Sichuan Biokin Pharmaceutical Submits Hong Kong IPO Application
Bailitanheng (688506) submitted an IPO prospectus and plans to go public in Hong Kong, jointly sponsored by Goldman Sachs, JPMorgan and Citic Securities.
On July 10, 2024, Sichuan Biokin Pharmaceutical Co., Ltd. (referred to as "Baili Tianheng", 688506.SH), a Shanghai star-listed company from Chengdu, Sichuan, submitted its prospectus to the Hong Kong Stock Exchange and plans to list on the Hong Kong main board.
No Data
No Data